Table 1. Included studies.

Study name		V501–007	V501–013	V501–015	V501–019	HPV–008	HPV–009	HPV–015	HPV–039	HPV–032/063
Trial number		NCT00365716	NCT00092521	NCT00092534	NCT00090220	NCT00122681	NCT00128661	NCT00294047	NCT00779766	NCT00316693
Year		2000–2004	2001–2007	2002–2007	2004–2009	2005–2010	2005–2012	2006–2012	2008–2014	2009–2013
Phase		III	III	III	III	III	III	III	II/III	II
Intervention		Gardasil	Gardasil	Gardasil	Gardasil	Cervarix	Cervarix	Cervarix	Cervarix	Cervarix
Comparator		Placebo	Placebo	Placebo	Placebo	Hep A vaccine	Hep A vaccine	Placebo	Placebo	Hep A vaccine
Country		International	International	International	International	International	Costa Rica	International	China	Japan
Key inclusion criteria
	Age	16–23	16–23	15–26	24–45	15–25	18–25	≥26	18–25	20–25
	Lifetime partners	0–4	0–4	0–4	Any	0–6	Any	Any	NR	NR
Endpoints
	Point prevalence at 4 years						x
	6-mo persistent infection			x	x	x			x
	12-mo persistent infection					x		x	x	x
	CIN1+	x	x	x		x		x	x	x
	CIN2+	x	x	x		x			x	x
Participants
	Total vaccine	9,087	2,723	6,087	1,910	9,319	3,727	2,877	3,026	375
	Total control	9,087	2,732	6,080	1,907	9,325	3,729	2,870	3,025	377
	SPDN vaccine	1,298	377	498	496	1,710	986	2,870	286	117
	SPDN control	1,319	379	524	505	1,777	980	2,908	270	90

CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; NR, not reported; SPDN, seropositive, DNA negative.